DK134098C - - Google Patents

Info

Publication number
DK134098C
DK134098C DK86073A DK86073A DK134098C DK 134098 C DK134098 C DK 134098C DK 86073 A DK86073 A DK 86073A DK 86073 A DK86073 A DK 86073A DK 134098 C DK134098 C DK 134098C
Authority
DK
Denmark
Application number
DK86073A
Other languages
Danish (da)
Other versions
DK134098B (da
Inventor
L Geller
Original Assignee
Ciba-Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CH229972A external-priority patent/CH574247A5/de
Application filed by Ciba-Geigy Ag filed Critical Ciba-Geigy Ag
Priority to DK500675A priority Critical patent/DK500675A/da
Publication of DK134098B publication Critical patent/DK134098B/da
Application granted granted Critical
Publication of DK134098C publication Critical patent/DK134098C/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/35Corticotropin [ACTH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DK86073AA 1972-02-17 1973-02-16 Fremgangsmåde til fremstilling af injicerbare olieholdige ACTH-peptidpræparater. DK134098B (da)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DK500675A DK500675A (da) 1972-02-17 1975-11-07 Fremgangsmade til fremstilling af injicerbare olieholdige peptidpreparater

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH229972A CH574247A5 (en) 1972-02-17 1972-02-17 Oily, injectable peptide/aluminium alkanoate compsns - - with prolonged duration of activity
CH1782972 1972-12-07

Publications (2)

Publication Number Publication Date
DK134098B DK134098B (da) 1976-09-13
DK134098C true DK134098C (en:Method) 1977-02-21

Family

ID=25690055

Family Applications (1)

Application Number Title Priority Date Filing Date
DK86073AA DK134098B (da) 1972-02-17 1973-02-16 Fremgangsmåde til fremstilling af injicerbare olieholdige ACTH-peptidpræparater.

Country Status (18)

Country Link
US (1) US3869549A (en:Method)
JP (1) JPS4892516A (en:Method)
AR (1) AR197116A1 (en:Method)
AT (1) AT335615B (en:Method)
AU (1) AU472655B2 (en:Method)
BE (1) BE795516A (en:Method)
CS (1) CS172967B2 (en:Method)
DD (1) DD102584A5 (en:Method)
DE (1) DE2306075A1 (en:Method)
DK (1) DK134098B (en:Method)
ES (1) ES411655A1 (en:Method)
FR (1) FR2181734B1 (en:Method)
GB (1) GB1418408A (en:Method)
IE (1) IE37151B1 (en:Method)
IL (1) IL41416A (en:Method)
NL (1) NL7300953A (en:Method)
PL (1) PL90318B1 (en:Method)
SE (1) SE7600435L (en:Method)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2254061A1 (de) * 1972-11-04 1974-05-16 Hoechst Ag Lh-releasing hormon zur nasalen applikation
DE2254043C2 (de) * 1972-11-04 1985-01-24 Hoechst Ag, 6230 Frankfurt LH-Releasing Hormon zur nasalen Applikation
JPS528375B2 (en:Method) * 1973-07-02 1977-03-09
GB1575343A (en) * 1977-05-10 1980-09-17 Ici Ltd Method for preparing liposome compositions containing biologically active compounds
JPS55118415A (en) * 1979-02-28 1980-09-11 Pii Papahadojiyopo Dometoriosu Method of encapsulating biologically active substance in lipoid cell
US4772466A (en) * 1983-08-22 1988-09-20 Syntex (U.S.A.) Inc. Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4770874A (en) * 1983-08-22 1988-09-13 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4933179A (en) * 1983-08-22 1990-06-12 Syntex (U.S.A.) Inc. Feline leukemia virus antigen vaccines
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
HU196714B (en) * 1984-10-04 1989-01-30 Monsanto Co Process for producing non-aqueous composition comprising somatotropin
US5411951A (en) * 1984-10-04 1995-05-02 Monsanto Company Prolonged release of biologically active somatotropin
US5474980A (en) * 1984-10-04 1995-12-12 Monsanto Company Prolonged release of biologically active somatotropins
US5086041A (en) * 1984-10-04 1992-02-04 Monsanto Company Methods of using prolonged release somatotropin compositions
DE3502099A1 (de) * 1985-01-23 1986-08-07 Dieter Prof. Dr. Dr. 5883 Kierspe Aderhold Therapeutisches, peptid- und/oder aminosaeurehaltiges mittel
US4650854A (en) * 1985-06-06 1987-03-17 Usv Pharmaceutical Corporation Amide analogs of calcitonin
US4804742A (en) * 1985-06-06 1989-02-14 Rorer Pharmaceutical Corporation Amide analogs of calcitonin
US4775659A (en) * 1985-08-19 1988-10-04 Eli Lilly And Company Injectable semi-solid formulations
ZA866218B (en) * 1985-08-23 1988-03-30 Lilly Co Eli Injectable sustained release formulation
US5554372A (en) * 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US5179079A (en) * 1986-12-16 1993-01-12 Novo Nordisk A/S Nasal formulation and intranasal administration therewith
US5635161A (en) * 1995-06-07 1997-06-03 Abbott Laboratories Aerosol drug formulations containing vegetable oils
KR19990071255A (ko) 1998-02-28 1999-09-15 성재갑 소마토트로핀과 비타민의 합제 조성물
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7258869B1 (en) * 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
NZ550320A (en) * 2004-04-15 2010-02-26 Chiasma Inc Compositions capable of facilitating penetration across a biological barrier
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
GB0511269D0 (en) * 2005-06-02 2005-07-13 Creative Peptides Sweden Ab Sustained release preparation of pro-insulin C-peptide
NZ572003A (en) 2006-05-30 2010-07-30 Intarcia Therapeutics Inc Two-piece, internal-channel osmotic delivery system flow modulator with spiral fluid channel
EP3421031A1 (en) 2006-08-09 2019-01-02 Intarcia Therapeutics, Inc Osmotic delivery systems and piston assemblies
WO2008133908A2 (en) 2007-04-23 2008-11-06 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
HUE043228T2 (hu) 2007-06-22 2019-08-28 Univ Texas Stabil szubmikron peptid vagy protein részecskék képzése vékonyfilm fagyasztással
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
MX348705B (es) 2008-09-17 2017-06-26 Chiasma Inc Composiciones farmacéuticas y métodos de administración relacionados.
EP2376522A4 (en) 2008-11-16 2013-12-25 Univ Texas HIGHLY CONCENTRATED LOW VISCOSITY SUSPENSIONS
PL2462246T3 (pl) 2009-09-28 2018-02-28 Intarcia Therapeutics, Inc Szybkie ustalenie i/lub zakończenie dostarczania leku zasadniczo w stanie równowagi dynamicznej
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2015158823A1 (de) 2014-04-16 2015-10-22 Veyx-Pharma Gmbh Veterinärpharmazeutische zusammensetzung und deren verwendung
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
PL3253401T3 (pl) 2015-02-03 2025-08-04 Amryt Endo, Inc. Leczenie akromegalii oktreotydem doustnym
JP6993235B2 (ja) 2015-06-03 2022-01-13 インターシア セラピューティクス,インコーポレイティド インプラントの設置及び撤去システム
CL2016000217A1 (es) * 2016-01-27 2016-07-01 Farmacologia En Aquacultura Veterinaria Fav S A Nueva composición veterinaria inyectable para la sincronización del desove en peces
US10501517B2 (en) 2016-05-16 2019-12-10 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
US10835580B2 (en) 2017-01-03 2020-11-17 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE950676C (de) * 1948-01-06 1956-10-11 Bristol Lab Inc Verfahren zur Herstellung eines injizierbaren Arzneimittels
DE920148C (de) * 1951-03-31 1954-11-15 Nyegaard & Co As Verfahren zur Herstellung von Adrenocorticotrophin-Praeparaten mit verlaengerter Wirkungsdauer
US2944940A (en) * 1956-01-16 1960-07-12 Armour & Co Adrenocorticotrophin and zinc composition
US2945783A (en) * 1957-06-20 1960-07-19 Reheis Company Inc Aluminum protein antacid and process of making

Also Published As

Publication number Publication date
DK134098B (da) 1976-09-13
AT335615B (de) 1977-03-25
IE37151L (en) 1973-08-17
FR2181734B1 (en:Method) 1975-10-10
FR2181734A1 (en:Method) 1973-12-07
BE795516A (fr) 1973-08-16
AR197116A1 (es) 1974-03-15
ATA140873A (de) 1976-07-15
DE2306075A1 (de) 1973-08-23
US3869549A (en) 1975-03-04
AU5218973A (en) 1974-08-15
CS172967B2 (en:Method) 1977-01-28
AU472655B2 (en) 1976-06-03
IL41416A (en) 1976-03-31
JPS4892516A (en:Method) 1973-11-30
DD102584A5 (en:Method) 1973-12-20
IL41416A0 (en) 1973-03-30
ES411655A1 (es) 1976-09-01
SE7600435L (sv) 1976-01-16
NL7300953A (en:Method) 1973-08-21
IE37151B1 (en) 1977-05-11
PL90318B1 (en:Method) 1977-01-31
GB1418408A (en) 1975-12-17

Similar Documents

Publication Publication Date Title
FR2181734B1 (en:Method)
FR2205518A1 (en:Method)
JPS4973528A (en:Method)
JPS4930002U (en:Method)
JPS5143561B2 (en:Method)
JPS494314A (en:Method)
JPS48113122U (en:Method)
JPS4988217U (en:Method)
JPS4974980A (en:Method)
JPS5137675Y2 (en:Method)
FR2168104A5 (en:Method)
RO61465A2 (en:Method)
JPS4955799U (en:Method)
FR2195885A1 (en:Method)
JPS4896612U (en:Method)
CH562719A5 (en:Method)
DD98717A1 (en:Method)
BG19985A1 (en:Method)
BG17144A1 (en:Method)
BG21773A1 (en:Method)
CH1163072A4 (en:Method)
SE7107743L (en:Method)
CH586588A5 (en:Method)
CH52272A4 (en:Method)
CH559254A5 (en:Method)